 |
Arena Pharmaceuticals Establishes BELVIQ® (lorcaserin HCl) Marketing and Supply Agreement with Ildong Pharmaceutical for South Korea
Nov 6, 2012
|
14.4 KB |
|
| |
SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd., for BELVIQ® (lorcaserin HCl). Under the agreement, Arena granted Ildong exclusive rights to mark...
|
|
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
Oct 31, 2012
|
10.1 KB |
|
| |
SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report third quarter 2012 financial results after the NASDAQ Global Select Market closes on Tuesday, November 6, 2012. The company will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m...
|
|
Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial of APD811 for Pulmonary Arterial Hypertension
Oct 12, 2012
|
10.9 KB |
|
| |
SAN DIEGO, Oct. 12, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).
This randomiz...
|
|
Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Sep 18, 2012
|
9.5 KB |
|
| |
SAN DIEGO, Sept. 18, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the UBS Global Life Sciences Conference on Thursday, September 20, 2012, at 7:30 a.m. Eastern Time (4:30 a.m. Pacific Time) at the Grand Hyatt New York in New York City.
A live...
|
|
Arena Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 30, 2012
|
11.3 KB |
|
| |
SAN DIEGO, Aug. 30, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present corporate updates at the following three upcoming investor conferences:
Stifel Nicolaus Healthcare ConferencePresentation: September 6, 2012, at 9:10 a.m. Eastern Time (6:10 a.m. Pacific Time) at th...
|
|
Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
Aug 9, 2012
|
25.5 KB |
|
| |
SAN DIEGO, Aug. 9, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the second quarter ended June 30, 2012, and reviewed recent developments.
At June 30, 2012, cash and cash equivalents totaled $143.8 million, which does not include (i) the $20.0 million milestone payment received from Eis...
|
|
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
Aug 2, 2012
|
10.2 KB |
|
| |
SAN DIEGO, Aug. 2, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will report second quarter 2012 financial results after the NASDAQ Global Select Market closes on Thursday, August 9, 2012. The company will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) that day to disc...
|
|
Eisai and Arena Pharmaceuticals Complete Transfer of BELVIQ® (lorcaserin HCl) New Drug Application
Jul 30, 2012
|
12.5 KB |
|
| |
WOODCLIFF LAKE, N.J., and SAN DIEGO, July 30, 2012 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Arena has transferred the BELVIQ® (lorcaserin hydrochloride) New Drug Application (NDA) to Eisai. The transfer establishes Eisai as the marketing authorization holder responsible for regulatory activ...
|
|
Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
Jul 11, 2012
|
11.2 KB |
|
| |
SAN DIEGO, July 11, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland. The intended indication is as an adjunct to diet and exercise for w...
|
|
Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
Jul 9, 2012
|
9.7 KB |
|
| |
SAN DIEGO, July 9, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Seventh Annual JMP Securities Healthcare Conference on Thursday, July 12, 2012, at 9 a.m. Eastern Time (6 a.m. Pacific Time) at The Peninsula New York Hotel in New York City. Craig M. Audet, Arena's Seni...
|
|
Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
Jul 5, 2012
|
11.0 KB |
|
| |
SAN DIEGO, July 5, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the promotion of Craig M. Audet to the position of Senior Vice President, Operations and Head of Global Regulatory Affairs. In his new role, Audet will serve as an executive officer of the company.
Audet, 48, will oversee various operations at ...
|
|
Arena Pharmaceuticals and Eisai Announce FDA Approval of BELVIQ® (lorcaserin HCl) for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese
Jun 27, 2012
|
23.0 KB |
|
| |
SAN DIEGO and WOODCLIFF LAKE, N.J., June 27, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients...
|
|
Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
May 21, 2012
|
11.5 KB |
|
| |
SAN DIEGO, May 21, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of an underwritten public offering of 12,650,000 shares of its common stock, including 1,650,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offere...
|
|
Arena Pharmaceuticals Prices Public Offering of Common Stock
May 16, 2012
|
11.6 KB |
|
| |
SAN DIEGO, May 16, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock, offered at a price to the public of $5.50 per share. The gross proceeds to Arena from this offering are expected to be $60.5 million, before deducting underwritin...
|
|
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 15, 2012
|
12.4 KB |
|
| |
SAN DIEGO, May 15, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms ...
|
|
Arena and Eisai Expand Marketing and Supply Agreement for Lorcaserin
May 10, 2012
|
15.5 KB |
|
| |
SAN DIEGO and WOODCLIFF LAKE, N.J., May 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the lorcaserin marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. Lorcaserin is an investigational drug can...
|
|
Lorcaserin Receives Positive Vote From FDA Advisory Committee
May 10, 2012
|
14.4 KB |
|
| |
SAN DIEGO and WOODCLIFF LAKE, N.J., May 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4, with one abstention, that the available data demonstrate that the potential benefits of lorcase...
|
|
Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
May 1, 2012
|
16.5 KB |
|
| |
SAN DIEGO, May 1, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the first quarter ended March 31, 2012, and reviewed recent developments.
"Lorcaserin has the potential to provide a new treatment option for the medical management of obesity," said Jack Lief, Arena's President and Chief E...
|
|
Arena Pharmaceuticals Announces European Medicines Agency's Acceptance of Lorcaserin Marketing Authorization Application for Weight Control
Mar 26, 2012
|
11.5 KB |
|
| |
SAN DIEGO, March 26, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in p...
|
|
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments
Mar 14, 2012
|
20.6 KB |
|
| |
SAN DIEGO, March 14, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2011, and reviewed recent developments.
"Lorcaserin has the potential to be an important option for physicians to address the medical management of obesity, helping patients...
|
